Non-clear cell renal cell carcinoma: How new biological insight may lead to new therapeutic modalities

Current Oncology Reports

Volumn 13, Issue 3, 2011, Pages 240-248

  Bex, Axel ^a   Larkin, James ^b   Blank, Christian ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chromophobe; Collecting duct; Metastatic renal cancer; Non clear cell renal cancer; Papillary; Subtypes; Targeted therapy; Xp11.2 translocation

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOKERATIN; DASATINIB; ERLOTINIB; EVEROLIMUS; EXELIXIS; FORETINIB; GEMCITABINE; IMATINIB; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NILOTINIB; ONARTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; XL 184;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CLASSIFICATION; CANCER RESEARCH; CHROMOSOME TRANSLOCATION X; CLEAR CELL CARCINOMA; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE ESCALATION; DRUG TARGETING; DYSPNEA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOXIA; KIDNEY CARCINOMA; LUNG METASTASIS; METASTASIS; NAUSEA; PAPILLARY CARCINOMA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; VOMITING;

CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, X; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; TRANSLOCATION, GENETIC;

EID: 79955921714     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-011-0159-y     Document Type: Review

References (66)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2001;18:581-92.
3. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798-805.
4. Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19:98-102. (Pubitemid 32410342)
5. Hutson TE, Bukowski RM, Cowey CL, et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011 Jan;77(1):48-62.
6. Vogelzang NJ, Samlowski W, Weissman A. Long-term response in primary renal cancer to sequential antiangiogenic therapy. J Clin Oncol. 2009;27:e106-7.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24. (Pubitemid 46089672)
8. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81. Data from a randomized controlled trial including patients with papillary RCC.
9. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272-80. Data of retrospective subgroup analyses of non-clear cell RCC treated with sorafenib.
10. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757-63. Data of retrospective subgroup analyses of non-clear cell RCC treated with sunitinib.
11. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients withmetastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2010. doi:10.1007/s10637-010-9491-6.
12. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127-31.
13. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009;27:5788-93.
14. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26:202-9.
15. Plimack ER, Jonasch E, Bekele BN, et al.: Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm phase II study. J Clin Oncol. 2010:28:4604. Prospective study involving patients with pRCC treated with sunitinib, only available as abstract.
16. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinico-pathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537-44. (Pubitemid 27293491)
17. Furge KA, MacKeigan JP, Teh BT. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol. 2010;11:571-8.
18. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68-73. (Pubitemid 27198158)
19. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155:517-26. (Pubitemid 29370401)
20. Morris MR, Gentle D, Abdulrahman M, et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005;65:4598-606. (Pubitemid 40740795)
21. Morris MR, Maher ER. Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med. 2010;2:59.
22. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther. 2009;9:785-93.
23. Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther. 2010;9:400-9.
24. Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal anti-body, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2010;16:699-710. Publication describing adverse events of AMG 102.
25. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 antic- Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008;68:4360-8.
26. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther. 2010;9:1544-53.
27. Yap TA, de Bono JS. Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther. 2010;9:1077-9.
28. Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol. 2008;26:5103.
29. Srinivasan R, Linehan W, Vaishampayan U, et al. A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). J Clin Oncol. 2009;27:5103. Prospective study [28•, 29•] involving patients with pRCC treated with foretinib, only available as abstract. Patients will be stratified according to MET status to evaluate an association with outcome.
30. Zhang Y, Guessous F, Kofman A, et al. XL-184, a MET, VEGFR- 2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs. 2010;13:112-21.
31. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005;11:2312-9. (Pubitemid 40490192)
32. Caglio S, Slimane K, May C, Escudier B. Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma. J Clin Oncol. 2010;28:15s. Describes the design of the RAPTOR trial.
33. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene. 2008;27:5511-26.
34. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68:8022-30.
35. Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008;68:6598-607.
36. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95-106. (Pubitemid 36793783)
37. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008;100:1260-2.
38. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8:143-53. (Pubitemid 41132743)
39. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77-85. (Pubitemid 40126384)
40. Jung CR, Hwang KS, Yoo J, et al. E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis. Nat Med. 2006;12:809-16. (Pubitemid 44050071)
41. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007;67:3171-6. (Pubitemid 46724854)
42. Yusenko MV, Kuiper RP, Boethe T, et al. High-resolution DNA copy number and gene expression analyses distinguish chromo-phobe renal cell carcinomas and renal oncocytomas. BMC Cancer. 2009;9:152.
43. Yusenko MV. Molecular pathology of chromophobe renal cell carcinoma: a review. Int J Urol. 2010;17:592-600.
44. Yusenko MV, Kovacs G. Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma. Histopathology. 2009;55:687-95.
45. Tan MH, Wong CF, Tan HL, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromo-phobe renal cell carcinoma and oncocytoma. BMC Cancer. 2010;10:196.
46. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2:157-64. (Pubitemid 41039116)
47. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA. 2006;103:15552-7. (Pubitemid 44625630)
48. Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg- Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst. 2008;100:140-54. (Pubitemid 351480566)
49. Woodward ER, Ricketts C, Killick P, et al. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. Clin Cancer Res. 2008;14:5925-30.
50. Stec R, Grala B, Maczewski M, et al. Chromophobe renal cell cancer-review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res. 2009;28:134.
51. Yamazaki K, Sakamoto M, Ohta T, et al. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 2003;22:847-52. (Pubitemid 36255820)
52. Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol. 2004;121:878-83. (Pubitemid 38669283)
53. Kruger S, Sotlar K, Kausch I, Horny HP. Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma. Oncology. 2005;68:269-75. (Pubitemid 41158986)
54. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055-63. (Pubitemid 350248462)
55. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol. 2009;27:9001.
56. Vuky J, Fotoohy M, Isacson C, et al. Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol. 2003;22: abstr 1672.
57. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World health organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC; 2004.
58. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22:1016-22.
59. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42:369-73.
60. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34:1295-303.
61. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919-29.
62. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010;116:5219-25. A retrospective review demonstrating effect of targeted therapy for translocation tumors.
63. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010;21:1834-8. A retrospective review demonstrating effect of first and second-line targeted therapy in 21 translocation tumors.
64. Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diagn Pathol. 1998;15:54-67. (Pubitemid 28093788)
65. Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol. 2007;177:1698-702. (Pubitemid 46560664)
66. Larkin J, Fisher R, Pickering L, et al. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib. J Clin Oncol. 2010;28:e539-40.